Vir Biotechnology (VIR) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Strategic vision and platform development

• Focus on transforming patient outcomes by leveraging immune system-based therapies, including antibody engineering and T-cell engager platforms.

• Recent acquisition of a masking T-cell engager platform to enhance targeted cancer therapies.

• Technologies address both infectious diseases and oncology, aiming for functional cures and chronic treatments.

Pipeline updates and clinical milestones

• Phase II programs in hepatitis B and delta are prioritized, with end-of-treatment and full data sets expected in Q4.

• Three clinical-stage T-cell engager programs (HER2, PSMA, EGFR) to advance, with phase I and II data expected in the next year.

• Upcoming R&D day to discuss hepatitis results, T-cell engager progress, and platform synergies.

Strategic restructuring and resource allocation

• Revenue decline post-pandemic led to pipeline reprioritization and workforce reduction by one-third.

• Infectious disease pipeline trimmed to focus on RSV prophylaxis and HIV cure; influenza, COVID, and viral vector programs phased out.

• Additional resources and expertise brought in through the Sanofi transaction.